Doxorubicin 10 Mg/5 Ml Fresenius, Doxorubicin 50 Mg/25 Ml Fresenius 10 mg/5 mL, 50 mg/25 mL Concentrate for solution for infusion
PDF Leaflet Revision Date: 09 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including leukaemias and solid tumors.
Dosage (summary)
60-90 mg/mu00b2 every 3-4 weeks; 0.4-0.5 mg/kg/day for acute leukaemias.
Special Populations
- Elderly
- Hepatic impairment
- Obese patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause fetal harm.
Key Drug Interactions
- Trastuzumab
- Cyclophosphamide
- CYP450 inhibitors
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Myocardial insufficiency
Common side effects
- Nausea
- Vomiting
- Leukopenia
- Cardiotoxicity
Counselling Points
- Avoid pregnancy during treatment
- Use effective contraception
- Monitor for signs of infection
Serious warnings
- Cardiotoxicity risk
- Myelosuppression
- Extravasation risk
Important Disclaimer
The Doxorubicin 10 Mg/5 Ml Fresenius, Doxorubicin 50 Mg/25 Ml Fresenius 10 mg/5 mL, 50 mg/25 mL Concentrate for solution for infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
